Top picks in English:
New positive data will aid Topotarget in its search for a European partner for a promising candidate drug, says an analyst. Although the price is going up, he still believes that the share is lower than it should be.
Top picks in English:
Danish researchers have discovered some of the damaging effects of bacteria. It lends hope to the pharmaceutical industry’s chances of treating even extremely complex bacterial infections. 
Top picks in English:
The latest data from a phase III study with Novo Nordisk’s haemophilia drug N9-GP are highly positive, says analyst Søren Løntoft Hansen and points out one factor that will determine the success of the drug on an extremely conservative market. 
Top picks in English:
Two of Novo Nordisk’s fiercest rivals have very distinct strategies in the battle for control of the global diabetes market. Medwatch has spoken to key people from Sanofi and Eli Lilly. 
Top picks in English:
Danish pharma giants Novo Nordisk and Lundbeck believe that common rules for medicine approvals could save the industry billions. 
Top picks in English:
The CEO of a Danish biotech company has struck a deal with two major organizations focusing on cancer immunotherapy, the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute and the European Association for Cancer Immunotherapy (CIMT). 
Top picks in English:
There is pressure on both the top and bottom line in Lundbeck, says an analyst, and the pressure is growing. The company can expect patent expirations on two drugs to cut almost a billion dollars of the company’s turnover in coming years. 
Top picks in English:
A new Danish discovery can prove crucial in understanding how novel drugs behave in a cell when targeting a disease. 
Top picks in English:
A Danish biotech has bought out its US partner for a million dollars and will develop its pipeline – which includes a promising diabetes candidate – alone in the future. 
Top picks in English:
Alcohol dependant Britons will be given access to Lundbeck’s new alcohol pill Selincro. It triggers a milestone payment for partner Biotie. 
Top picks in English:
FDA has agreed to review a registration application for a new oral ragweed allergy vaccine submitted by Danish company ALK-Abello and commercial partner Merck. 
Top picks in English:
The US is going to be the major driving force for ALK-Abello’s growth in coming years, but the company is also working with several models for penetrating the markets in China, Brazil and Russia. 
Top picks in English:
Texas lawyers are ready to take class action against Novo Nordisk in a case concerning side effects from diabetes drug Victoza. 
Top picks in English:
REBBLS is the name of a new network for young bio-entrepreneurs, who are already living their entrepreneurial dreams. The focus is on collaboration and not just causal coffeehouse conversations. 
Top picks in English:
Seed Capital sees major investment opportunities within the life science sector, although just three of the venture fund's 16 European investments in 2012 were in this area. 
Top picks in English:
The Danish diabetes giant, Novo Nordisk, is ready with a new large investment in its home country, which will create jobs in the town Kalundborg. 
Top picks in English:
The special status given to a candidate drug from Genmab could cut years off the development. The company’s CEO has talked to Medwatch about the future of the company following a number of promising announcements. 
Top picks in English:
The US patent on best-selling drug Lexapro expired long ago and other crucial patent expirations are on the way for Lundbeck. Alzheimer drug Ebixa expires during H2 2013 and Cipralex is next in line in 2014. See which drugs could end up determining the future of the Danish company. 
Top picks in English:
US medicines authorities, FDA, have awarded the coveted breakthrough designation to a candidate drug from Danish biotech Genmab. It could lead to an accelerated market entrance for the drug and had an immediate effect on the company share. 
Top picks in English:
Schizophrenia pills with microchips could be the next major area of collaboration between Lundbeck and Otsuka, who both see a huge potential in the technology. 
Top picks in English:
The CFO of Novo Nordisk, Jesper Brandgaard, explains more about the ongoing dialogue with the FDA in regards to additional studies of diabetes drug Tresiba, and reveals what the US sales force will be used for until the time of approval. 
Top picks in English:
At BIO 2013 in Chicago Medwatch met up with a US company that can offer an alternative to needle-based injections, for the benefit of Danish Novo Nordisk and its rivals on the global diabetes market. 
Top picks in English:
A 25-year-old university ace has teamed up with a group of colleagues to develop drugs against snake poison. 
Top picks in English:
Medicon Valley Alliance is about to open a new office in the US. Medwatch met with the new guy over there and MVA’s already-stationed employee in Boston for a talk about MVA's efforts on the American market. 
Top picks in English:
The Danish biotech Veloxis has applied for marketing authorization from the EMA for a candidate drug aimed at ensuring kidney transplant patients do not reject the new organ. 
Top picks in English:
One of the most prominent analysts and venture capitalists in the biotech industry offered his take on the development in the sector in 2012, as well as a crucial mantra for success, at the recently held BIO 2013 conference in Chicago. 
Top picks in English:
Growth rates are plummeting in the Icelandic prosthetics group Össur and, although acquisitions have long been a vital part of the strategy, the group’s top executive is keeping a cool head.
Top picks in English:
According to Ernst & Young there is a disturbing development in the global biotech industry due to a lack of belief in future prospects in the sector. But Denmark counters this trend in a very crucial way.
Top picks in English:
It requires sound scientific data and a strong initial effort to convince a certain group of doctors as Lundbeck prepares to market its new pill against alcohol dependence. 
Top picks in English:
Few days after becoming a major shareholder in the Danish biotech company, Neurosearch, Swiss bank UBS is selling all its shares again. It is not the first time the bank has used the tactic. 
Top picks in English:
2012 was an eventful year for Swiss pharma outfit Novartis, which is also reflected in both the bottom and top lines of the company’s financial report for the first quarter of 2013 in spite of the effects from patent expirations. 
Top picks in English:
Founder, Chairman of the board and major shareholder in Bavarian Nordic calls the Danish company’s latest million-dollar-contract “the first step in the final industrialisation of Bavarian Nordic”. 
Top picks in English:
According to Sanofi’s global diabetes chief, recent debate over concerns about an increased risk of pancreatic inflammation linked to the diabetes drug type GLP-1 will have an impact on the FDA’s view on the drug class. 
Top picks in English:
The product portfolio in the Danish company Exiqon is now expanded with new panels for preclinical toxicological research. 
Top picks in English:
Monday the Danish pharmaceutical group Lundbeck launched its drug for alcohol dependance on a number of markets – read on to see which. 
